Item |
Mean |
SD |
Overarching principles |
7.23 |
3.04 |
Item-1 (starting DMARDs early) |
8.62 |
2.60 |
Item-2 (remission-monitoring) |
9.49 |
1.44 |
Item-3 (Methotrexate) |
9.05 |
2.05 |
Item-4 (DMARDs other than MTX) |
7.99 |
2.21 |
Item-5 (Monotherapy rather than combination) |
6.28 |
3.09 |
Item-6 (Adding GCs) |
8.86 |
2.10 |
Item-7 (Biologics when poor prognosis) |
8.55 |
2.02 |
Item-8 (responding insufficiently, start TNF inhibitors) |
8.67 |
1.98 |
Item-9 (Failure in first TNF inhibitor,
start another TNF inhibitor or other biologics) |
8.22 |
2.25 |
Item-10 (Refractory severe RA or biologics
contraindicated other synthetic DMARDs ) |
7.87 |
2.24 |
Item-11 (Intensive medication strategies) |
8.80 |
1.87 |
Item-12 (Persistent remission tapering of biologics) |
8.15 |
2.29 |
Item-13 (Sustained long-term remission, cautious
titration of synthetic DMARD) |
8.73 |
1.86 |
Item-14 (Poor prognostic factors combination
of MTX with a biologic) |
7.68 |
2.76 |
Item-15 (progression of structural damage,
comorbidities and safety concerns) |
9.41 |
1.42 |
Self-declared application of overall recommendations, % |
72.42 |
20.53 |